Danaher (BVL:DHR) - Stock Price, News & Analysis

DHR Stock Overview

Designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.

DHR fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	2/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 16.2% below our estimate of its fair value

Earnings are forecast to grow 14.28% per year

Risk Analysis

Significant insider selling over the past 3 months

Danaher Corporation Competitors

Thermo Fisher Scientific

NYSE:TMO

US$231.3b

IQVIA Holdings

NYSE:IQV

US$45.2b

Agilent Technologies

NYSE:A

US$40.4b

Lonza Group

SWX:LONN

CHF 39.8b

Price History & Performance

Summary of all time highs, changes and price drops for Danaher
Historical stock prices
Current Share Price	US$250.50
52 Week High	US$250.50
52 Week Low	US$250.50
Beta	0.86
11 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	DHR	PE Life Sciences	PE Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how DHR performed against the PE Life Sciences industry.

Return vs Market: Insufficient data to determine how DHR performed against the PE Market.

Price Volatility

Is DHR's price volatile compared to industry and market?
DHR volatility
DHR Average Weekly Movement	0%
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in PE Market	0%
10% least volatile stocks in PE Market	0%

Stable Share Price: DHR has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DHR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1969	62,000	Rainer Blair	www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.

Danaher Corporation Fundamentals Summary

How do Danaher's earnings and revenue compare to its market cap?
DHR fundamental statistics
Market cap	US$193.60b
Earnings (TTM)	US$4.06b
Revenue (TTM)	US$23.57b

47.9x

P/E Ratio

8.2x

P/S Ratio

Is DHR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DHR income statement (TTM)
Revenue	US$23.57b
Cost of Revenue	US$9.48b
Gross Profit	US$14.09b
Other Expenses	US$10.03b
Earnings	US$4.06b

Last Reported Earnings

Jun 28, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	5.62
Gross Margin	59.78%
Net Profit Margin	17.21%
Debt/Equity Ratio	34.1%

How did DHR perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

19%

Payout Ratio

Danaher BVL:DHR Stock Report